CDC: Yellow fever vaccine stock now depleted | Vorinostat studied for GVHD prevention after unrelated donor stem cell transplants | Intraocular bleeding compared for novel oral anticoagulants, warfarin
August 18, 2017
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
CDC: Yellow fever vaccine stock now depleted
The CDC announced the loss of a large stock of yellow fever vaccine during a Sanofi Pasteur plant relocation and said the US-licensed vaccine will not be available again until next year. The FDA has cleared Sanofi to bring in Stamaril, a yellow fever vaccine made in France, under the investigational drug program.
Becker's Hospital Review (8/16) 
LinkedIn Twitter Facebook Google+ Email
Science & Health
Vorinostat studied for GVHD prevention after unrelated donor stem cell transplants
A midstage study in the journal Blood found that 32% of patients treated with vorinostat prophylaxis developed acute graft-versus-host disease in the year after hematopoietic stem cell transplantation from an 8/8 HLA-matched unrelated donor to treat a hematologic malignancy. After 30 days, levels of GVHD biomarkers were lower in patients treated with vorinostat.
Healio (free registration) (8/15) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Intraocular bleeding compared for novel oral anticoagulants, warfarin
A meta-analysis of 12 late-stage randomized clinical trials by Australian researchers found that the use of novel oral anticoagulants resulted in a decline in intraocular bleeding in comparison to the use of warfarin for patients with venous thromboembolism or atrial fibrillation. The study in JAMA Ophthalmology included the NOACs apixaban, dabigatran, edoxaban and rivaroxaban.
eMPR (8/14) 
LinkedIn Twitter Facebook Google+ Email
Gates Foundation to invest more than $300M in Tanzania
The Bill & Melinda Gates Foundation has pledged to invest more than $300 million in public health and poverty elimination programs in Tanzania this year. "I see a chance for the eradication of malaria and HIV/AIDS, but that's gonna take a lot of science and a lot of investment," Bill Gates said.
Reuters (8/13) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Transmedics' Organ Care System extends viability of heart for transplant
Transmedics developed a portable perfusion and monitoring console dubbed the Organ Care System, which is capable of pumping blood through a heart being transported for transplant and may allow the organ to remain viable longer as it travels to its intended recipient. The system is being tested by physicians at Vanderbilt University Medical Center.
WTVF-TV (Nashville, Tenn.) (8/17) 
LinkedIn Twitter Facebook Google+ Email
Novel assay detects malaria in 30 seconds
Singapore University of Technology and Design researchers have developed a malaria diagnostic test that is portable, cost-efficient and can produce results within half a minute. The improved cytometer has a color camera and raised lens and counts cells by using machine-learning algorithms and image processing.
The Straits Times (Singapore) (free content) (8/18) 
LinkedIn Twitter Facebook Google+ Email
Blood test spots early-stage cancer DNA
A blood test that detects DNA fragments released by malignant tumors accurately diagnosed 71% of early-stage colon cancers, 68% of early-stage ovarian cancers and 59% of early-stage breast and lung cancers in 200 patients previously diagnosed with cancer; and yielded no false positives in 44 cancer-free volunteers, researchers reported in Science Translational Medicine. More work on the assay is needed, but the ability to diagnose cancer at very early stages could save lives, says lead researcher Victor Velculescu.
HealthDay News (8/16) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Pfizer's Besponsa for ALL gets FDA nod
Pfizer's Besponsa, or inotuzumab ozogamicin, was approved by the FDA as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Seeking Alpha (free registration) (8/17) 
LinkedIn Twitter Facebook Google+ Email
Alexion adds patents to Soliris
Alexion has gained three new patents for its expensive biologic drug Soliris, or eculizumab, for paroxysmal nocturnal hemoglobinuria. Amgen has a potential eculizumab biosimilar in its pipeline.
FiercePharma (8/16) 
LinkedIn Twitter Facebook Google+ Email
Association News
Technical Manual, 19th Edition, now available for pre-order
The Technical Manual, 19th Edition, is now available for pre-order in the AABB Marketplace. This resource covers the entire spectrum of blood collection and transfusion, and provides professionals of all levels the information they need to succeed in this rapidly changing field. Those who pre-order the Technical Manual will save $10 off the retail price through Sept. 30.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Medical Officer / Dep. Director, Center for Cellular Engineering
There is no waste of any kind in the world that equals the waste from needless, ill-directed and ineffective motions.
Frank Bunker Gilbreth,
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information